Drug shortage: Dexamethasone Sodium Phosphate Injection (DEXAMETHASONE SODIUM PHOSPHATE)
FDA lists 19 presentations as Current. Availability: Unavailable (4), Available (15). Reason: Demand increase for the drug. Companies: Eugia US LLC, Hikma Pharmaceuticals USA, Inc., Mylan Institutional, a Viatris Company, Somerset Therapeutics, LLC, Fresenius Kabi USA, LLC.
- Published by source
- 2019-02-08
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Eugia US LLC
- Products
- Dexamethasone Sodium Phosphate Injection DEXAMETHASONE SODIUM PHOSPHATE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Check wholesalers for inventory
- Additional product will be made available as it is released.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2019-02-08
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #907 | new | 2026-10-22 | 07727f0b06a8…c3dd16 | 24feaa8429da…3158a0 |
Chain head: #1076 8ad5adc30b9b…88ce20